Compare Amphastar Pharmaceuticals Inc (AMPH) vs Citigroup Inc. (C) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Citigroup (C) trades at $134.99, up 0.86% with bullish technical momentum near key resistance at $136. The stock shows strong fundamental improvement with Q2 2026 EPS beating estimates at $3.15 versus $2.72 expected, marking the second consecutive quarterly beat. Revenue reached decade highs in Q2 2026 at $91.4B with net income margin improving to 19.52%. Recent strategic hires in investment banking and digital transformation initiatives support growth prospects.

The outlook remains positive with analyst consensus target of $154.38 offering 14% upside potential. Key risks include volatile cash flow patterns with negative operating cash flow in 2025 ($-67.6B) and elevated debt levels at $287.3B long-term debt. The stock's current P/E of 14.55 appears reasonable given improving profitability and strategic repositioning underway.